OTCMKTS:GSGTF

GenSight Biologics News Headlines

$9.35
0.00 (0.00 %)
(As of 09/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.35
$9.35
50-Day Range
$6.10
$9.90
52-Week Range
$3.10
$11.30
VolumeN/A
Average Volume1,639 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Media Mentions By Week

GenSight Biologics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

GSGTF
News Sentiment

0.94

0.30

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

GSGTF Articles
This Week

1

0

GSGTF Articles
Average Week

Get GenSight Biologics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GSGTF and its competitors with MarketBeat's FREE daily newsletter.

GenSight Biologics (OTCMKTS GSGTF) News Headlines Today

SourceHeadline
GenSight Biologics Announces Positive Data Safety Monitoring Board Review of PIONEER Phase I/II Clinical Trial of GS030 as Optogenetic Treatment for Retinitis PigmentosaGenSight Biologics Announces Positive Data Safety Monitoring Board Review of PIONEER Phase I/II Clinical Trial of GS030 as Optogenetic Treatment for Retinitis Pigmentosa
finance.yahoo.com - September 15 at 2:26 AM
GenSight Biologics Announces Publication Analyzing Visual Parameters of ND4-LHON Subjects Before LUMEVOQ® Treatment in Phase III TrialsGenSight Biologics Announces Publication Analyzing Visual Parameters of ND4-LHON Subjects Before LUMEVOQ® Treatment in Phase III Trials
finance.yahoo.com - September 9 at 1:55 AM
GenSight Biologics (OTCMKTS:GSGTF) Trading 53.3% Higher GenSight Biologics (OTCMKTS:GSGTF) Trading 53.3% Higher
americanbankingnews.com - September 9 at 12:56 AM
UK MHRA Grants GenSight Biologics LUMEVOQ® Ophthalmic Gene Therapy Promising Innovative Medicine DesignationUK MHRA Grants GenSight Biologics' LUMEVOQ® Ophthalmic Gene Therapy Promising Innovative Medicine Designation
benzinga.com - September 6 at 4:37 AM
UK MHRA Grants GenSight Biologics’ LUMEVOQ® Ophthalmic Gene Therapy Promising Innovative Medicine DesignationUK MHRA Grants GenSight Biologics’ LUMEVOQ® Ophthalmic Gene Therapy Promising Innovative Medicine Designation
finance.yahoo.com - September 6 at 4:37 AM
Clinical Data on GenSight Biologics’ LUMEVOQ® and GS030 Gene Therapies to be Presented at 2021 ISGEDR and Several Investor and Industry Meetings in SeptemberClinical Data on GenSight Biologics’ LUMEVOQ® and GS030 Gene Therapies to be Presented at 2021 ISGEDR and Several Investor and Industry Meetings in September
finance.yahoo.com - September 1 at 4:07 PM
GenSight Biologics Announces Publication of RESTORE Study Data Demonstrating Sustained Efficacy 3 Years After Unilateral Injection of LUMEVOQ®GenSight Biologics Announces Publication of RESTORE Study Data Demonstrating Sustained Efficacy 3 Years After Unilateral Injection of LUMEVOQ®
finance.yahoo.com - August 31 at 2:53 AM
GenSight Biologics Reports Interim Financial Results for the First Half of 2021 and Provides Operational UpdateGenSight Biologics Reports Interim Financial Results for the First Half of 2021 and Provides Operational Update
finance.yahoo.com - July 29 at 8:41 AM
GenSight Biologics to Host Key Opinion Leader Webcasts on the Topline Results from REFLECT Phase III Clinical Trial of LUMEVOQ®GenSight Biologics to Host Key Opinion Leader Webcasts on the Topline Results from REFLECT Phase III Clinical Trial of LUMEVOQ®
finance.yahoo.com - July 5 at 2:33 PM
GenSight Biologics Announces Approval of the LUMEVOQ® Cohort Temporary Authorization for Use (ATUc) in FranceGenSight Biologics Announces Approval of the LUMEVOQ® Cohort Temporary Authorization for Use (ATUc) in France
finance.yahoo.com - July 5 at 8:53 AM
GenSight Biologics Reports Topline Results from REFLECT Phase III Clinical Trial, Confirming LUMEVOQ® Efficacy Including Better Efficacy with Bilateral TreatmentGenSight Biologics Reports Topline Results from REFLECT Phase III Clinical Trial, Confirming LUMEVOQ® Efficacy Including Better Efficacy with Bilateral Treatment
finance.yahoo.com - June 30 at 10:18 AM
GenSight Biologics Appoints Marion Ghibaudo as Chief Technical Officer to Lead GS030 Device EngineeringGenSight Biologics Appoints Marion Ghibaudo as Chief Technical Officer to Lead GS030 Device Engineering
benzinga.com - June 10 at 4:40 AM
GenSight Biologics Announces Publication of...GenSight Biologics Announces Publication of...
benzinga.com - June 1 at 9:27 AM
GenSight Biologics to Host a Key Opinion Leader Webinar on the Nature Medicine Case Report: Visual Recovery after GS030 Optogenetic TreatmentGenSight Biologics to Host a Key Opinion Leader Webinar on the Nature Medicine Case Report: Visual Recovery after GS030 Optogenetic Treatment
benzinga.com - May 31 at 8:31 AM
GenSight Biologics Appoints Françoise de Craecker to its Board of DirectorsGenSight Biologics Appoints Françoise de Craecker to its Board of Directors
benzinga.com - May 17 at 7:58 AM
GenSight Biologics Reports Cash Position as of...GenSight Biologics Reports Cash Position as of...
benzinga.com - April 20 at 8:25 AM
GenSight Biologics Announces the Publication in Communications Biology of the Proof-of-Concept for GS030-Drug Product in Non‑Human PrimatesGenSight Biologics Announces the Publication in Communications Biology of the Proof-of-Concept for GS030-Drug Product in Non‑Human Primates
benzinga.com - February 4 at 9:57 AM
GenSight Biologics Announces its 2021 Financial CalendarGenSight Biologics Announces its 2021 Financial Calendar
markets.businessinsider.com - January 19 at 4:22 PM
GenSight Biologics Announces the Partial Conversion of Convertible Bonds and Full Exercise of Share Warrants by Kreos CapitalGenSight Biologics Announces the Partial Conversion of Convertible Bonds and Full Exercise of Share Warrants by Kreos Capital
benzinga.com - December 10 at 6:07 PM
EMA accepts GenSight gene therapy application for inherited vision loss disorderEMA accepts GenSight gene therapy application for inherited vision loss disorder
seekingalpha.com - November 3 at 7:49 AM
GenSight Biologics S.A. (GSGTF)GenSight Biologics S.A. (GSGTF)
nasdaq.com - October 22 at 6:27 PM
The GenSight Biologics (EPA:SIGHT) Share Price Is Down 63% So Some Shareholders Are Wishing They SoldThe GenSight Biologics (EPA:SIGHT) Share Price Is Down 63% So Some Shareholders Are Wishing They Sold
finance.yahoo.com - October 22 at 1:27 PM
How Much Did GenSight Biologics S.A.s (EPA:SIGHT) CEO Pocket Last Year?How Much Did GenSight Biologics S.A.'s (EPA:SIGHT) CEO Pocket Last Year?
finance.yahoo.com - October 22 at 1:27 PM
GenSight Biologics Reports Final REALITY Natural History Study Results Confirming Poor Spontaneous Recovery for LHON Patients With ND4 MutationGenSight Biologics Reports Final REALITY Natural History Study Results Confirming Poor Spontaneous Recovery for LHON Patients With ND4 Mutation
finance.yahoo.com - October 22 at 8:26 AM
GenSight Biologics Reports Interim Financial Results for the First Half of 2020 and Provides Operational UpdateGenSight Biologics Reports Interim Financial Results for the First Half of 2020 and Provides Operational Update
finance.yahoo.com - October 22 at 8:26 AM
GenSight Biologics Draws Down the €4 Million Second Tranche of Bonds From Kreos CapitalGenSight Biologics Draws Down the €4 Million Second Tranche of Bonds From Kreos Capital
finance.yahoo.com - October 22 at 8:26 AM
Gensight Biologics Successfully Raises €25 Million in an Oversubscribed Private Placement With Us and European Institutional InvestorsGensight Biologics Successfully Raises €25 Million in an Oversubscribed Private Placement With Us and European Institutional Investors
finance.yahoo.com - October 22 at 8:26 AM
Get GenSight Biologics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GSGTF and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 9/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.